ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 697,94
0,47%
Dow Jones
39 112,16
-0,76%
DAX
18 351,62
1,04%
Brent Oil
84,515
0,39%
Bitcoin
61 701,30
-0,18%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ACELYRIN Inc (SLRN)

  7. ACELYRIN Inc (SLRN) Actualités

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateHeureSourceTitreSymboleSociété
11/06/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
05/06/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
28/05/202423h20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
25/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
14/05/202422h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
09/05/202414h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
09/05/202414h01GlobeNewswire Inc.ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesNASDAQ:SLRNACELYRIN Inc
09/05/202414h00GlobeNewswire Inc.ACELYRIN, INC. Announces Leadership TransitionNASDAQ:SLRNACELYRIN Inc
29/04/202422h05GlobeNewswire Inc.ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024NASDAQ:SLRNACELYRIN Inc
28/03/202421h05GlobeNewswire Inc.ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
27/03/202421h01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:SLRNACELYRIN Inc
20/03/202412h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
11/03/202413h02GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisNASDAQ:SLRNACELYRIN Inc
11/03/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsNASDAQ:SLRNACELYRIN Inc
15/02/202422h05GlobeNewswire Inc.ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsNASDAQ:SLRNACELYRIN Inc
12/01/202411h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
20/12/202322h30GlobeNewswire Inc.ACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsNASDAQ:SLRNACELYRIN Inc
12/12/202314h00PR Newswire (US)DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Acelyrin, Inc. (NASDAQ: SLRN) and Lead Plaintiff DeadlineNASDAQ:SLRNACELYRIN Inc
28/11/202312h03IH Market NewsTuesday’s Wall Street Highlights: Zscaler, Shein, 3M, Meta Platforms, and MoreNASDAQ:SLRNACELYRIN Inc
27/11/202322h30GlobeNewswire Inc.ACELYRIN, INC. Provides Update on Izokibep Clinical Development ProgramNASDAQ:SLRNACELYRIN Inc
07/11/202322h05GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
06/11/202313h00GlobeNewswire Inc.ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations OfficerNASDAQ:SLRNACELYRIN Inc
31/10/202321h30GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023NASDAQ:SLRNACELYRIN Inc
03/10/202313h00GlobeNewswire Inc.ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of DevelopmentNASDAQ:SLRNACELYRIN Inc
12/09/202315h23IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:SLRNACELYRIN Inc
12/09/202313h29IH Market NewsTuesday’s Wall Street Highlights: Apple, Acelyrin, WestRock, Oracle, UPS, and moreNASDAQ:SLRNACELYRIN Inc
12/09/202302h03Dow Jones NewsStocks to Watch: Oracle, Acelyrin, HumacyteNASDAQ:SLRNACELYRIN Inc
11/09/202322h05GlobeNewswire Inc.ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis SuppurativaNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN

Dernières Valeurs Consultées

KOSPI
028670
Pan Ocean
NASDAQ
LGTOW
Legato Merger Corporatio...
LSE
56BA
Res.mtg.14 A2aa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés